Halozyme appoints David Ramsay as Interim CFO effective March 23, 2026

HALOZYME THERAPEUTICS, INC.

Monthly salary of $50,000; initial grant of 10,000 RSUs vesting June 30, 2026, plus 2,500 more if still interim after July 1.
Ramsay previously served as Halozyme CFO from 2003-2009 and 2013-2015, and guided company from private to public.
Company is actively searching for a permanent CFO via a leading executive search firm.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.